与myc结合亲和力高的已上市药物

MYC有所谓不可成药性，还没有专门的靶向药上市。

目前针对myc实际可行的治疗策略是根据患者除myc突变扩增外的其他突变，抑制其他靶点，如mtor、hsp90等，实现合成致死或蛋白降解。自救群里部分myc扩增的乳腺癌患者用了mtor抑制剂，确有疗效。
0 Z  L+ h* X. Q
针对治疗myc还有一种办法是通过计算机虚拟筛选等办法，在已上市药物里找与myc结合亲和力高的药物。
) s9 [, f8 b' Q1 Y
9 N8 ?4 n0 [* f. g+ f' a《In Silico, In Vitro, and In Vivo Investigations on Adapalene as Repurposed Third Generation Retinoid against Multiple Myeloma and Leukemia》这篇论文，通过Virtual Screening、Molecular Docking Analyses and Microscale Thermophoresis的办法，从FDA已经批准上市的1578种药物里，筛选出一些与MYC结合亲和力高的药物；其中一些药物与MYC的结合亲和力超过常用的c-MYC 抑制剂试剂 10058-F4 和 10074-G5(LBEs of −4.92 kcal/mol and −6.24 kcal/mol)。
  D  |; N+ S) H1 I, v; f2 ?* {
下面是结合亲和力比较强的一些药物：

5 |9 B( Y" @( C5 O
1 ]/ ~* N1 U/ ]/ e; ^8 `' x
$ Y, O+ N0 [. Z: t2 J8 m
7 b/ O8 B$ `! W' \5 C其他一些研究的结论与这篇论文的结论是相印证的，试举几例如下：
$ ~6 w+ `# D% [- z, J
( F5 c# B3 I9 L7 g% d
/ m6 D8 J4 `: f1、《Targeting Oncogenic Super Enhancers in MYC-Dependent AML Using a Small Molecule Activator of NR4A Nuclear Receptors》
) k* H8 g/ R1 p' M' g9 G8 a: p
! \3 c- g) k4 [+ h9 |“MYC was identified as the most statistically repressed gene by DHE”

7 R  H4 y# D8 ^& J
3 d# F& T. j3 F6 `; t
2、《Drug repurposing and prediction of multiple interaction types via graph embedding》

4 l. w' @3 x) P" k“Two FDA approved drugs, Dihydroergotamine (CHEMBL1732) and Indinavir Sulfate (CHEMBL1735), which are predicted by the DT2Vec+, might be able to target MYC and decrease its expression. ”


9 l! K2 o& p5 k0 Z2 n0 e' G# ]
" `& j4 p. H: R3、《Involvement of MCL1, c-myc, and cyclin D2 protein degradation in ponatinib-induced cytotoxicity against T315I(+) Ph+leukemia cells》

“PNT induced apoptosis (increased sub G1 cells, and cleaved caspase3 and PARP), and suppressed protein expression of MCL1, cyclin D2 and c-myc, which were reversed by a proteasome inhibitor, MG132, suggesting enhanced proteasomal degradation by PNT. ”

3 D1 N4 ?0 v( ]1 a6 Z
4、《 Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer》
: {4 S7 @+ a% G" z4 C
Additionally, treatment with eribulin resulted in a decrease in c-myc expression and a trend
toward an increase in cdki p15。
' `4 H+ g- ?; k3 H4 v8 y, |8 b& k% C& v

7 o- |% q8 P% W% h7 J8 S5、《Atovaquone: an antiprotozoal drug suppresses primary and resistant breast tumor growth by inhibiting HER2/β-catenin signaling》

“We also observed a decrease in c-Myc expression in the tumors of atovaquone-treated mice”